Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03960177 · ClinicalTrials.gov registry record · Early Phase 1
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
A Early Phase 1 study of Osteosarcoma, sponsored by OHSU Knight Cancer Institute.
- Active
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT03960177 is a Early Phase 1 study of Osteosarcoma that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 12 participants, below the 302-participant average among 46 other Osteosarcoma trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03960177, a Early Phase 1 study of Osteosarcoma, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients' blood and lead to shorter hospitalizations and a reduction in toxicities.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Glucarpidase
Study Locations (3)
Florida
- Mayo Clinic in Florida - Jacksonville
Oregon
- OHSU Knight Cancer Institute - Portland
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03960177
The ClinicalTrials.gov registry entry for NCT03960177 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 46 other Osteosarcoma trials with a reported enrollment target (96% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03960177 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03960177 about?
NCT03960177 is a clinical study titled "Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma". This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients' blood and lead to shorter hospitalizations and a reduction in toxicities.
What is the current status of trial NCT03960177?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2019-03-27. Estimated completion is 2026-12-31.
What conditions does trial NCT03960177 study?
This clinical trial studies the following conditions: Osteosarcoma.
What interventions are being tested in trial NCT03960177?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Glucarpidase (DRUG).
Who is sponsoring clinical trial NCT03960177?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03960177 being conducted?
This trial has 3 study locations across Florida, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
RECRUITING · Phase 3
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.